Contrasting Humacyte (HUMA) & Its Peers

Humacyte (NASDAQ:HUMA) is one of 844 public companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare Humacyte to related businesses based on the strength of its earnings, institutional ownership, analyst recommendations, profitability, valuation, risk and dividends.

Insider and Institutional Ownership

44.7% of Humacyte shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 3.1% of Humacyte shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Humacyte and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Humacyte	1	1	6	0	2.62
Humacyte Competitors	9874	15295	45659	1600	2.54

Humacyte presently has a consensus price target of $4.48, suggesting a potential upside of 702.52%. As a group, “Biotechnology” companies have a potential upside of 126.20%. Given Humacyte’s stronger consensus rating and higher possible upside, research analysts clearly believe Humacyte is more favorable than its peers.

Earnings and Valuation

This table compares Humacyte and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Humacyte	$2.04 million	-$40.83 million	-1.27
Humacyte Competitors	$703.08 million	$9.72 million	-18.76

Humacyte’s peers have higher revenue and earnings than Humacyte. Humacyte is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Humacyte and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Humacyte	-3,955.05%	-612.88%	-80.03%
Humacyte Competitors	-12,319.70%	-407.93%	-30.95%

Volatility and Risk

Humacyte has a beta of 2.64, meaning that its share price is 164% more volatile than the S&P 500. Comparatively, Humacyte’s peers have a beta of -1.84, meaning that their average share price is 284% less volatile than the S&P 500.

Summary

Humacyte peers beat Humacyte on 7 of the 12 factors compared.

Humacyte Company Profile

Humacyte, Inc. is a biotechnology company developing bioengineered human tissues for vascular repair and other medical applications. Its technology uses human vascular cells to create vessels that are processed to remove the cells, leaving an acellular structure designed for implantation. The company’s lead product, Symvess, is an acellular tissue-engineered vessel for treating extremity arterial injuries in adults when a patient’s own vein cannot be used for surgical revascularization. The U.S. Food and Drug Administration approved Symvess in December 2024.